It's How Medicine Should Be®
Services & Conditions

Conditions and Treatments

View Alphabetically

Find a Doctor
Advanced Doctor Search >

Doctors at Rush Focus on You

Octavio Vega, MDAt the end of the visit, my goal is to have the patients feel more informed and to feel like their issues have been properly addressed.

— Octavio Vega, MD, internist

Patricia Graham, MDI enjoy the challenges of piecing together the puzzle – putting difficult, complicated signs and symptoms together and trying to formulate a diagnosis.

— Patricia Graham, MD, internist

Hear more from doctors at Rush.

Patients & Visitors

Patients

Directions and Parking

Locations
Health & Wellness

Health News and Advice to Fit Your Life

The choices you make each day can have a huge effect on your health. Rush offers a wealth of resources to help you make good ones.

Maintaining a Healthy WeightMan riding bike on beachTips to help you overcome common barriers to weight maintenance.

Six Signs of Nutrient DeficiencyWoman washing carrots in sinkHair loss, headaches and other signs you may be missing key vitamins and minerals.

 

About Us

Translate

French German Italian Portuguese Russian

Treatment Study for Patients With Soft Tissue Sarcoma

Clinical Trial Title: 
A phase Ib trial of neoadjuvant AMG 232 concurrent with preoperative radiotherapy in wild-type P53 soft tissue sarcoma (STS).
Clinical Trial Protocol ID: 
18010902
Clinical Trial Investigator Name: 
Dian Wang, MD, PhD
Clinical Trial Protocol Description: 

This phase Ib trial studies the side effects of MDM2 inhibitor AMG-232 and radiation therapy in treating patients with soft tissue sarcoma. MDM2 inhibitor AMG-232 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving MDM2 inhibitor AMG-232 and radiation therapy before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed.

Clinical Trial Eligibility Criteria: 

In order to participate you must meet the following criteria:

  • Have pathologically proven diagnosis of grade 2-3 (intermediate or high grade) soft tissue sarcoma.
  • Have a planned definitive surgical resection of the primary tumor.
  • Have an Eastern Cooperative Oncology Group (ECOG) or Zubrod performance status of 0-1 within 30 days prior to registration.

This is a partial list of inclusion and exclusion criteria.

Clinical Trial Area: 
Sarcomas
Contact Phone: 
(312) 942-8892
Contact Name: 
Jean Gibson, RN